Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: A systematic review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 2857-2863

  Zhang, Xinji ^a   Qin, Yingyi ^a   Li, Hui ^a   Bai, Chong ^b   Zhu, Tianyi ^b   Xu, Jinfang ^a   Wu, Cheng ^a   Wu, Mengjie ^a   Wang, Chaoxiang ^a   Song, Hualing ^c   Wei, Lixin ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Epidermal growth factor receptor; Meta analysis; Multi targeted therapy; Non small cell lung cancer; Vandetanib; Vascular endothelial growth factor receptor

Indexed keywords

EID: 84863325015     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Borenstein M, Hedges LV, Higgins JPT, Rothstein H.2009 (Editors) Introduction to meta-analysis. John Wiley & Sons, Ltd., United Kingdom.
2. Carlomagno F, Vitagliano D, Guida T, et al (2002). ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, effi ciently blocks oncogenic RET kinases. Cancer Res, 62, 7284-90.
3. Ciardiello F, Troiani T, Bianco R, et al (2006). Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 17 SUPPL, 7, vii109-14.
4. de Boer RH, Arrieta O, Yang CH, et al (2011). Vandetanib pluspemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol, 29, 1067-74.
5. Deeks J, Higgins, JPT, et al. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0.
6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
7. Gatzemeier U, Pluzanska A, Szczesna A, et al (2007). Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 25, 1545-52.
8. Giaccone G, Herbst RS, Manegold C, et al (2004). Gefi tinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol, 22, 777-84.
9. Hanrahan EO, Ryan AJ, Mann H, et al (2009). Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefi t from vandetanib in non-small cell lung cancer. Clin Cancer Res, 15, 3600-9.
10. Herbst RS, Giaccone G, Schiller JH, et al (2004). Gefi tinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol, 22, 785-94.
11. Herbst RS, Prager D, Hermann R, et al (2005). TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 23, 5892-9.
12. Herbst RS: (2006). Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 8 Suppl, 1, S23-30.
13. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ: (2007). Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs, 16, 239-49.
14. Herbst RS, Sun Y, Eberhardt WE, et al (2010). Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol, 11, 619-26.
15. Heymach JV, Johnson BE, Prager D, et al (2007). Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol, 25, 4270-7.
16. Heymach JV, Paz-Ares L, De Braud F, et al (2008). Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as fi rst-line treatment for advanced non-small-cell lung cancer. J Clin Oncol, 26, 5407-15.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
18. Ioannidis JP, Trikalinos TA. (2007). The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ, 176, 1091-6.
19. Jadad AR, Moore RA, Carroll D, et al (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 17, 1-12.
20. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
21. Johnson BE, Ryan AJ, Heymach J, et al (2010). Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. J Clin Oncol (suppl; abstr 7516), 28, 15s.
22. Kim ES, Hirsh V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 372,1809-18.
23. Kiura K, Nakagawa K, Shinkai T, et al (2008). A randomized, double-blind, phase IIa dose-fi nding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol, 3, 386-93.
24. Lee J, Hirsh V, Park K, et al (2010). Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol (suppl; abstr 7525), 28, 15s.
25. Maemondo M et al. (2010). Gefi tinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8.
26. Natale RB, Bodkin D, Govindan R, et al (2009). Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol, 27, 2523-9.
27. Natale RB, Thongprasert S, Greco FA, et al (2011). Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol, 29, 1059-66.
28. Naumov GN et al (2009). Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res, 15, 3484-94.
29. Parmar MK, Torri V, Stewart L. (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
30. Ricciardi S, Tomao S, de Marinis F. (2009). Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer, 10, 28-35.
31. Sandler A, Gray R, Perry MC, et al, (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355, 2542-50.
32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.
33. Stewart LA, Parmar MK, (1993). Meta-analysis of the literature or of individual patient data: is there a difference? Lancet, 341, 418-22.
34. Wedge SR, Ogilvie DJ, Dukes M, et al. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res, 62, 4645-55.